Mesothelioma study with RNA-Seq, WXS data on dbGaP (122 participants)

phs002207 — Genomic and Transcriptomic Profiling of Patients with Malignant Pleural    and Peritoneal Mesothelioma: The NCI Cohort

Malignant mesothelioma is an aggressive cancer with limited treatment options and poor prognosis. Better understanding of mesothelioma genomics and transcriptomics could advance novel therapies. We performed whole-exome sequencing (WXS) of germline and tumors of 122 patients, and RNA-sequencing (RNA-Seq) of tumor samples of 100 patients with pleural, peritoneal, and tunica-vaginalis mesothelioma. The biospecimens used in this study were collected as a part of the Mesothelioma Natural History Protocol (<a href="https://clinicaltrials.gov/ct2/show/NCT01950572">https://clinicaltrials.gov/ct2/show/NCT01950572</a>), wherein, samples were collected from subjects with malignant mesothelioma as listed in the eligibility criteria below and written consent from each participant was obtained before sample acquisition.